Deaf girl is cured in world first gene therapy trial

Mechanism of the Therapy (Not CRISPR)

• Commenters clarify this is AAV-based gene therapy, not CRISPR.
• An adeno‑associated virus delivers otoferlin cDNA into inner‑ear hair cells.
• The DNA remains as an episome (circular extra-chromosomal DNA), not integrated into the genome, reducing risk of disrupting other genes.
• Hair cells do not turn over during life, so a “protein factory” in those cells could provide durable benefit.

Prospects for Other Conditions

• Strong interest in applying similar approaches to:
  • Red‑green color blindness (fixing opsin genes in cones).
  • Retinitis pigmentosa and other inherited retinal diseases.
  • Other monogenic hearing losses (e.g., GJB2/connexin 26, STRC; specific pipelines cited).
• Some note regulatory bodies currently see gene therapy risk as too high for non‑severe conditions like color blindness.

Subjective Experience of Gaining a New Sense

• Curiosity about how it feels to gain hearing or new color perception later in life.
• Discussion of brain plasticity, “critical periods,” and mixed evidence: some abilities must be learned early, but adults can also adapt to major sensory changes.
• Personal anecdotes about regaining smell or improving vision illustrate both wonder and difficulty of adaptation.

Deaf Culture, Disability, and Ethics

• Several note parts of the Deaf community oppose cochlear implants and may resist gene therapy, seeing deafness as identity (“deaf gain”), not defect.
• Fears include cultural loss, pressure to “fit in” to hearing society, and echoes of eugenics.
• Others argue restoring a nonfunctional sense is clearly beneficial, likening deafness to lacking legs rather than being short.
• Broader debate over where to draw the line between therapy and enhancement, and who decides (individuals vs parents vs state).

Regulation, Safety, and DIY Bio

• Historical gene‑therapy setbacks (e.g., a high‑profile death) are cited as reasons for slow progress.
• Discussion of FDA’s role: protecting patients vs allowing high‑risk elective treatments; proposal of a “middle tier” approval.
• DIY gene editing and self‑experimentation are criticized as reckless; laypeople may be unable to grasp all risks.

Costs, Access, and Inequality

• Enthusiasm is tempered by concern that advanced therapies will be extremely expensive and mainly available to the privileged.
• Broader worries about U.S. healthcare costs, insurance gaps, and misaligned incentives in pharma and medical practice.

Personal Stories and Emotional Impact

• Deaf and hard‑of‑hearing commenters share experiences with cochlear implants, otosclerosis, and IVF with genetic screening.
• Some celebrate the news as evidence that medical science is one of the few consistent sources of hope amid wider societal problems.